{"id":6662,"date":"2024-11-21T14:51:34","date_gmt":"2024-11-21T13:51:34","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6662"},"modified":"2025-04-28T21:51:46","modified_gmt":"2025-04-28T19:51:46","slug":"tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-rationale-305-randomised-double-blind-phas","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-rationale-305-randomised-double-blind-phas\/","title":{"rendered":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6662","publication","type-publication","status-publish","hentry","disease_state-gastic-gastroesophageal-junction-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6662"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}